AB
TRVI icon

Amalgamated Bank’s Trevi Therapeutics TRVI Stock Holding History

Amalgamated Bank’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,852
Closed -$36K – 2732
2025
Q4 		$36K Buy
2,852
+284
+11% +$3.28K ﹤0.01% 1922
2025
Q3 		$23K Hold
2,568
– – ﹤0.01% 2073
2025
Q2 		$14K Hold
2,568
– – ﹤0.01% 2289
2025
Q1 		$16K Buy
2,568
+1,165
+83% +$5.56K ﹤0.01% 2166
2024
Q4 		$6K Hold
1,403
– – ﹤0.01% 2687
2024
Q3 		$5K Hold
1,403
– – ﹤0.01% 2784
2024
Q2 		$4K Hold
1,403
– – ﹤0.01% 2889
2024
Q1 		$5K Sell
1,403
-2,228
-61% -$4.97K ﹤0.01% 2745
2023
Q4 		$5K Sell
3,631
-418
-10% -$633 ﹤0.01% 2945
2023
Q3 		$9K Hold
4,049
– – ﹤0.01% 2918
2023
Q2 		$10K Buy
+4,049
New +$10.2K ﹤0.01% 2961

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Amalgamated Bank's TRVI Position: Q1 2026 in Review

Amalgamated Bank sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 2,852 shares — an estimated $36K sold.

Amalgamated Bank first reported a position in TRVI in Q2 2023 and held it in 11 quarters. The position peaked at $36K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Amalgamated Bank reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,852 Trevi Therapeutics shares in Q1 2026, an estimated $36K.
  • Amalgamated Bank first reported a position in Trevi Therapeutics in Q2 2023 and held it in 11 quarters.
  • Amalgamated Bank's Trevi Therapeutics position peaked at $36K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.